Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:: The Era of Oncodermatopathology

Jonathan L Curry; Susan Y Chon; Mario L Marques-Piubelli; Emily Y Chu

doi:10.1016/j.path.2021.01.002

Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:: The Era of Oncodermatopathology

Surg Pathol Clin. 2021 Jun;14(2):209-224. doi: 10.1016/j.path.2021.01.002. Epub 2021 Apr 28.

Authors

Jonathan L Curry¹, Susan Y Chon², Mario L Marques-Piubelli³, Emily Y Chu⁴

Affiliations

¹ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jlcurry@mdanderson.org.
² Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ Department of Dermatology, The University of Pennsylvania, Philadelphia, PA 19104, USA.

PMID: 34023101
DOI: 10.1016/j.path.2021.01.002

Abstract

Advancements in cancer therapy with monoclonal immune checkpoint antibody blockade have impacted the practice of all medical specialties. Cutaneous immune-related adverse events (irAEs) are a frequent, unintended, off-target consequence of immune checkpoint inhibitor (ICI) therapy that have ushered in the era of oncodermatopathology. Knowledge of the diverse morphologic types of cutaneous irAEs from ICI therapy allows further classification of cutaneous irAEs according to major histopathologic reaction patterns. Early studies suggest that immune mechanisms of lichenoid dermatitis irAE, psoriasiform dermatitis irAE, and bullous pemphigoid irAE show some similarities and differences from their histopathologic counterparts not associated with ICI therapy.

Keywords: Cutaneous toxicities; Immune checkpoint inhibitor; Oncodermatopathology.

Publication types

Review

MeSH terms

Humans
Immune Checkpoint Inhibitors*
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors